Search

Your search keyword '"D Bhojwani"' showing total 161 results

Search Constraints

Start Over You searched for: Author "D Bhojwani" Remove constraint Author: "D Bhojwani"
161 results on '"D Bhojwani"'

Search Results

1. Outcomes after perioperative SARS-CoV-2 infection in patients with proximal femoral fractures: an international cohort study

2. Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trialResearch in context

4. 278 The Paediatric Major Trauma Tertiary Survey: Are We Missing the Mark on Missed Injuries?

5. 330 An End to Doctor’s Handwriting in the Digital Age: Evaluating the Legibility of Operation Notes in Otolaryngology

6. Small bowel intussusception and concurrent jejunal polyp with neoplastic transformation: a new diagnosis of Peutz-Jeghers syndrome

7. 374 Simulation and the Surgeon during COVID-19: The Double 2s Surgical Emergencies Course

8. Measurement of intraocular pressure in children in the UK

9. Gene Expression Profiling Differentiates childhood Acute Lymphoblastic Leukemia in Down Syndrome Versus Non - Down Syndrome Patients

11. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia

12. Clinical Actionability of the NUDT15 *4 (p.R139H) Allele and Its Association With Hispanic Ethnicity.

13. Vincristine Sulfate Liposome Injection with Combination Chemotherapy for Children, Adolescents, and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial.

14. Budget impact analysis of TPMT and NUDT15 pharmacogenomic testing for 6-mercaptopurine in pediatric acute lymphoblastic leukemia patients.

15. CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells.

16. Progression of brain injuries associated with methotrexate chemotherapy in childhood acute lymphoblastic leukemia.

17. Pediatric therapy-related hematologic neoplasms show enrichment for KMT2A rearrangement and lymphoblastic phenotype.

18. Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study.

19. Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium.

20. Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy-An observational Ponte di Legno Toxicity Working Group Study.

21. Acute Hemophagocytic Lymphohistiocytosis Due to Tularemia.

22. Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial.

24. IKZF1 PLUS alterations contribute to outcome disparities in Hispanic/Latino children with B-lymphoblastic leukemia.

25. Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations.

26. B-cell acute lymphoblastic leukemia and juvenile xanthogranuloma in a patient with ETV6 thrombocytopenia and leukemia predisposition syndrome: novel clinical presentation and perspective.

27. Cold burn injuries in the United Kingdom: retain-->A 5-year cohort study of patients presenting to a regional burn unit.

28. Nationwide Etoricoxib Injection Clinical Experience (NICE): Real-World Evidence in Indian Patients.

30. Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.

31. Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group.

32. Transcriptome Sequencing Allows Comprehensive Genomic Characterization of Pediatric B-Acute Lymphoblastic Leukemia in an Academic Clinical Laboratory.

33. INSPIRED Symposium Part 4A: Access to CAR T Cell Therapy in Unique Populations with B Cell Acute Lymphoblastic Leukemia.

34. Children's Oncology Group blueprint for research: Acute lymphoblastic leukemia.

35. Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.

36. Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population.

37. Surgical Triumph Over Metatarsal Osteosarcoma: A Rare Case Report Revealing Diagnostic Challenges and Successful Management.

38. Artemis inhibition as a therapeutic strategy for acute lymphoblastic leukemia.

39. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells.

40. Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial.

41. Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding.

42. Atypical Manifestation of VZV Infection in a Vaccinated Immunocompetent Adult.

43. Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium.

44. Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.

45. Characterization of PAX5 intragenic tandem multiplication in pediatric B-lymphoblastic leukemia by optical genome mapping.

46. Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia.

47. Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype.

48. Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.

49. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.

50. Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.

Catalog

Books, media, physical & digital resources